Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion type Assertion NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_head.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion description "[We treated 32 patients with Ph1-negative chronic myeloproliferative disorders (CMD) with excessive thrombocytosis with Interferon alpha-2b (IFN alpha-2b): 26 had essential thrombocythaemia, ET (18 previously untreated, eight pretreated); one thrombocythaemia after treatment for Hodgkin's disease (HD); two thrombocythaemia associated with non-Hodgkin's lymphoma (NHL); three stage II idiopathic myelofibrosis (IM).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion evidence source_evidence_literature NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion SIO_000772 2757963 NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion wasDerivedFrom befree-2016 NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.
- NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_assertion wasGeneratedBy ECO_0000203 NP1296598.RAsru-v1iV5NrWNM_N5VoexmzgwQWQmNWEe--mOaOi0kI130_provenance.